---
schema_version: "secwatch.filing_event.v1"
accession: "0001453687-26-000090"
form_type: "8-K"
ticker: "RNAC"
cik: "0001453687"
company_name: "Cartesian Therapeutics, Inc."
filed_at: "2026-06-17T20:01:15+00:00"
generated_at: "2026-06-17T20:02:22.564370+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Cartesian Therapeutics shareholders elect three Class I directors, approve say-on-pay and auditor

## Summary
- Michael Singer, Timothy Springer, and Patrick Zenner elected Class I directors through 2029.
- Non-binding advisory vote on named executive officer compensation approved (13.7M for, 136K against).
- Ratification of Ernst & Young as independent auditor for FY2026 approved (24.1M for).
- Approximately 82.42% of outstanding shares represented at June 12, 2026 annual meeting.

## SEC filing metadata
- accession: 0001453687-26-000090
- form_type: 8-K
- ticker: RNAC
- cik: 0001453687
- company_name: Cartesian Therapeutics, Inc.
- filed_at: 2026-06-17T20:01:15+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453687/000145368726000090/0001453687-26-000090-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453687/000145368726000090/rnac-20260612.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001453687-26-000090
- JSON: https://secwatch.observer/filing/0001453687-26-000090.json
- Plain text: https://secwatch.observer/filing/0001453687-26-000090.txt

## Key facts
- Shareholder Votes
  Cartesian Therapeutics, Inc. shareholders approved Approval, on a non-binding and advisory basis, of a resolution approving the compensation of the Company's named executive officers. at the 2026-06-12 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-12
  source text: Proposal 2 - Approval, on a non-binding and advisory basis, of a resolution approving the compensation of the Company’s named executive officers. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 13,659,709 136,217 6,033,199 4,322,411 Based on the votes set forth above, the stockholders approved, on a non-binding and advisory basis, a resolution approving the compensation of our named executive officers.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1453687/000145368726000090/0001453687-26-000090-index.htm
- Shareholder Votes
  Cartesian Therapeutics, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026. at the 2026-06-12 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-12
  source text: Proposal 3 - Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 24,144,742 6,157 637 — Based on the votes set forth above, the stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1453687/000145368726000090/0001453687-26-000090-index.htm
- Shareholder Votes
  Cartesian Therapeutics, Inc. shareholders approved Election of three Class I Directors to serve until the 2029 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified. at the 2026-06-12 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-12
  source text: Proposal 1 - Election of three Class I Directors to serve until the 2029 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified. NOMINEE Votes FOR Votes WITHHELD Broker Non-Votes Michael Singer, M.D., Ph.D. 11,745,619 8,083,506 4,322,411 Timothy A. Springer, Ph.D. 18,665,163 1,163,962 4,322,411 Patrick Zenner, M.B.A 12,168,919 7,660,206 4,322,411 Based on the votes set forth above, each director nominee was duly elected to serve until the Company’s 2029 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1453687/000145368726000090/0001453687-26-000090-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.